

numares technology offers performance and robustness: 500,000 lipoprotein tests in US laboratory

Regensburg, 03/26/2015 – The U.S. based laboratory HEALTH DIAGNOSTIC LABORATORY Inc. (HDL, Inc.) has performed 500,000 tests for the determination of lipoproteins since the first devices were installed at HDL, Inc. nine months ago. The tests were run on several NMR devices and in routine operation. The technology and expertise for these special laboratory diagnostics in the field of cardiovascular disease were provided by numares HEALTH. The in vitro diagnostics manufacturer numares HEALTH supported HDL Inc. to successfully develop a powerful and robust test system. This laid the foundation for a close development partnership with the U.S. company.

Approximately 50,000 analyses per month are now processed at HDL Inc. since the systems were commissioned in March 2014. Dr. Joseph McConnell, CEO and co-founder of HDL Inc. enthusiastically explains: *“The performance and robustness of both method and instruments is exceptional.”* The US company contacted numares in 2012 seeking support and expertise in the development of a high throughput method for determining lipoprotein particles. Lipoproteins transport cholesterol and other fats in the human blood and play an important role in the pathogenesis of atherosclerosis and several other cardiovascular diseases.

numares HEALTH specializes in the development of test systems for human diagnostics based on nuclear magnetic resonance (NMR) spectroscopy. The company uses its NMR competence to perform a highly accurate and simultaneous determination of metabolites in bodily fluids. Using innovative evaluation approaches, metabolic profiles are determined that describe the condition of the patient and so provide the physician with valuable diagnostic information. numares had as early as 2004 developed a method based on NMR, which determines the concentration and size of lipoprotein particles in the blood. According to current scientific opinion, the data obtained with this method allows a better risk assessment of cardiovascular diseases than determining standard parameters such as HDL and LDL cholesterol alone.

To date, the operation and use of NMR instruments has been reserved for NMR specialists. With the development and commercialization of its user-friendly IVD test systems numares now offers all laboratories the ability to perform NMR-based assays in routine operation and high throughput without special knowledge.

numares will continue to work closely with the HDL, Inc. in the future. "With our help, HEALTH DIAGNOSTIC LABORATORY Inc. will develop further tests and integrate them into these systems. Our IVD systems allow various diagnostic issues to be investigated on just one device, sometimes

based on a single sample measurement", informs Dr. Volker Pfahlert, Chairman of the Executive Board of numares AG.

"We are also leading discussions with experts in the fields of cardiology, metabolism and laboratory diagnostics to get our test into routine clinical practice. The goal is to make these revolutionary diagnostics available for every patient in Europe," comments co-founder and board member Dr. Fritz Huber regarding the plans for the European market launch of a separate numares test system for determining lipoprotein particles which starts early this year.

About numares

numares GROUP develops and markets new analytical and diagnostic products based on nuclear magnetic resonance (NMR) spectroscopy in the fields of medicine, plant breeding and biotechnology.

The business unit numares HEALTH develops and markets in-vitro diagnostic tests with the CE marking and integrated test systems for high-throughput use in clinical diagnostics and life science research. The highly standardized tests provide valuable information on the disease status of patients in the indication areas of cardiovascular diseases, nephrology and oncology.

In addition, numares HEALTH provides its test systems to the pharmaceutical industry on a fee-for-service basis. They can be used for example to investigate the therapeutic effects of drugs as part of clinical trials. The company also supports customers with complex issues and clinical trials, drawing on its many years of expertise and experience in the area of NMR spectroscopy and metabolomics.

www.numares-health.com

For further information please contact:

numares AG

Dipl.-Biol. Christiane Proll, MBA

tel.: +49 941 2809 49-14

email: christiane.proll@numares-health.com

IRA WÜLFING KOMMUNIKATION GmbH

Dr. Reinhard Saller

Tel.: +49 89 2000 30-38

E-Mail: reinhard.saller@wuelfing-kommunikation.de



About Health Diagnostic Laboratory, Inc.

Founded in 2008, Health Diagnostic Laboratory, Inc. (HDL, Inc.) is an innovation driver in health management with one mission: prevent and reverse heart disease and diabetes, one patient at a time. The company offers a comprehensive test menu of biomarkers that can indicate risk for cardiovascular disease, diabetes, and related diseases. HDL, Inc.'s systematic approach identifies factors contributing to disease and provides a basis for effective treatment, allowing healthcare providers to more effectively manage their patients.

In addition to lab testing, HDL, Inc. offers patients a personalized overview of risk factors and assistance from expert Clinical Health Consultants to promote healthy, longer-lasting lifestyles. The company also provides comprehensive testing and wellness services to employers and is a partner for value-based, integrated care models and health systems.

HDL, Inc. is a CLIA-certified, CAP-accredited laboratory. For more information, visit myHDL.com, and make HDL, Inc. part of your digital lifestyle at [Facebook.com/myhdl](https://www.facebook.com/myhdl) and on Twitter [@hdltweets](https://twitter.com/hdltweets).

For further information please contact:

Health Diagnostic Laboratory Inc.

Mr. Jeff Kelley, Director of Marketing and Public Relations

Tel.: +1 804.370.3257

E-Mail: jkelly@hdlabinc.com